ASP3082 grabs some early attention among degraders set to feature at ESMO.

Early attention falls on ADCs originated by ProfoundBio, SystImmune, MediLink and Seagen.

The FDA throws out the company’s second attempt at an accelerated approval.

While Roche, Lilly and Merck push on aggressively, Novartis throws in the towel.

Now in Bristol’s hands, BMS-986442 is set to deliver its first clinical data.

The group reaffirms pancreatic cancer promise with RMC-6236, but has it found the best dose?